ACT in action.

Fecal microbiota transplantation (FMT), significantly reduced recurrence of hepatic encephalopathy compared with placebo in patients with cirrhosis on standard-of-care treatment, results of a phase 2 randomized controlled trial show.

Achieving Cures Together research partner, Dr. Jasmohan Bajaj at the Virginia Commonwealth University’s School of Medicine, in collaboration with Dr. Alexander Khoruts at the University of Minnesota, is studying the link between microbial health, Advanced Liver Disease and alcohol cravings. An early clinical trial demonstrated the safety of microbiota transplant therapy in patients. A new clinical trial aims to investigate the impact of this therapy in a larger group.

Researchers in California have discovered specific gut bacteria strains useful in detecting liver fibrosis and cirrhosis with an accuracy of greater than 90 percent.